Ciglitazone对裸鼠肝癌移植瘤的血管生成的抑制作用

目的 观察过氧化物酶体增殖激活受体配体Ciglitazone在肝癌治疗中对血管生成的作用.方法 3周龄裸鼠随机分为实验组(10只)、对照组(10只).皮下接种HepG2肝癌细胞,待肿瘤生长至约0.5 cm时,实验组瘤内注射100 μmol/L的Ciglitazone 100 μl,对照组注射100μ生理盐水,隔天注射连续15次.逆转录-聚合酶链反应(RT-PCR)检测第31天的肝癌组织标本内PPAR的表达,免疫组织化学法和蛋白质定量分析法(Western blot)测定癌组织中因子Ⅷ和VEGF的表达.结果 肝癌组织内存在PPAR的表达,实验组PPARγ表达增高[(1.26±0.29)比(0.32 ±0.11),P<0.05],实验组的瘤块体积小、生长慢于对照组[(207.5 ±192.9)mm3比(445.0 ±150.9)mm3;P<0.05],实验组裸鼠体内肿瘤MVD低于对照组[(11.0 ±7.6)比(18.9 ±7.0),P<0.05];实验组裸鼠体内肿瘤VEGF的表达低于对照组(17.2±3.7比47.9 ±11.3,P<0.01).结论 Ciglitazone对肝癌的生长具有抑制作用,抗肿瘤血管形成可能是其中的作用机制之一.

Inhibitory effect of dglitazone on tumor angiogenesis in nude mice transplants of hepatic carcinoma

Objective To investigate the effect of ligand of peroxisome proliferator-activated receptor gamma (PPAR) on tumor angiogenesis in nude mice transplants of hepatic carcinoma. Methods RT-PCR was use to detect the PPAR mRNA expression in hepatic carcinoma tissuse, and the expression of Ⅷ factor and VEGF in the ciglitazone-treated nude mice transplants of hepatic carcinoma was assayed by using SP method and Western blot. Results PPAR mRNA was detected in tumor,and in ciglitazone-treated group,tumor grew slowly [ (207.5 + 192.9) mm3 ,P <0.05 ]. The MVD and VEGF expression in ciglitazone-treated group were lower than in control group ( P < 0.05 and P < 0.01, respectively). Conclusion Ciglitazone can inhibit the growth of hepatic carcinoma by suppressing the angiogenesis.